



Altimune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference

October 1, 2024 at 7:30 AM EDT

GAITHERSBURG, Md., Oct. 01, 2024 (GLOBE NEWSWIRE) -- [Altimune, Inc.](#) (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that its Chief Executive Officer, Vipin Garg, Ph.D., and Chief Medical Officer, Scott Harris, M.D., will participate in a fireside chat at the H.C. Wainwright 8th Annual MASH Virtual Conference:

Conference: *H.C. Wainwright 8th Annual MASH Virtual Conference*

Presenters: *Vipin Garg, Ph.D., Chief Executive Officer
Scott Harris, M.D., Chief Medical Officer*

Date/Time: *Monday, October 7, 2024, at 11:30 a.m. EDT*

The session will be webcast and can be accessed by visiting the [Events](#) section of the Altimune website.

About Altimune

Altimune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). For more information, please visit www.altimmune.com.

Follow @Altimune, Inc. on [LinkedIn](#)

Follow @AltimuneInc on [Twitter](#)

Company Contact:

Vipin Garg
President and Chief Executive Officer
Phone: 240-654-1450
ir@altimmune.com

Media Contact:

Danielle Cantey
Inizio Evoke, Biotech
Phone: 619-826-4657
Danielle.cantey@inizioevoke.com

Investor Contact:

Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com

Julia Weilman
Burns McClellan
Phone: 646-732-4443
jweilman@burnsmc.com

This press release was published by a CLEAR® Verified individual.



Source: Altimune, Inc